Zura Bio Limited (Nasdaq: ZURA) has concluded a private placement that generated approximately $80 million in gross proceeds. 

This funding milestone enables the company to commence a Phase 2 clinical trial for ZB-106, initially targeting systemic sclerosis (SSc) and subsequently conducting a Phase 2 clinical trial for hidradenitis suppurativa (HS).

$ZURA was trading at $7.88 in pre-market, up $1.39 (+21.42%), following the announcement. 

PDS Biotechnology Corporation (Nasdaq: PDSB) will hold a conference call and webcast to discuss the encouraging interim data from the VERSATILE-002 Phase 2 clinical trial.

The trial investigates PDS0101 in combination with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), and was presented at the 2023 American Society for Clinical Oncology (ASCO) meeting. The event is scheduled for June 6 at 8:00 a.m. ET.

In anticipation of the conference call, $PDSB is experiencing positive pre-market trading, currently at $7.55, displaying an increase of $1.02 (+15.62%).

THOR Industries, Inc. (NYSE: THO) reported third-quarter fiscal 2023 earnings per share (EPS) of $2.24, surpassing the consensus estimate of $1.07. 

Furthermore, the company has raised the lower end of its full-year fiscal 2023 diluted earnings per share guidance, increasing the range from $5.50 to $6.50 to the updated range of $5.80 to $6.50, which exceeds the consensus estimate of $5.64 for the period.

In pre-market, $THO was trading at $85.00, showcasing an increase of $5.84 (+7.38%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)